Interleukin-6: Minor player or starring role in the development of hormone-refractory prostate cancer?

BJU International

Volumn 91, Issue 6, 2003, Pages 545-553

  Corcoran, N M ^a   Costello, A J ^a,b  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; CISPLATIN; DEXAMETHASONE; ETOPOSIDE; GLYCOPROTEIN GP 130; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE;

CANCER GROWTH; CANCER THERAPY; CYTOTOXICITY; HUMAN; MEDICAL LITERATURE; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS, HORMONAL; DRUG RESISTANCE, NEOPLASM; HUMANS; INTERLEUKIN-6; MALE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RECEPTORS, INTERLEUKIN-6; SIGNAL TRANSDUCTION;

EID: 0037690822     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2003.04025.x     Document Type: Review

References (74)

1. Huggins C, Hodges CV. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293-7
2. Mahler C, Denis L. Management of relapsing disease in prostate cancer. Cancer 1992; 70: 329-34
3. Gnanapragasam VJ, Robson CN, Leung HY, Neal DE. Androgen receptor signalling in the prostate. BJU Int 2000; 86: 1001-13
4. Hellawell GO, Brewster SF. Growth factors and their receptors in prostate cancer. BJU Int 2002; 89: 230-40
5. Miki S, Iwano M, Miki Y et al. Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett 1989; 250: 607-10
6. Miles SA, Rezai AR, Salazar-Gonzalez JF et al. AIDS Kaposi sarcoma-derived cells produce and respond to interleukin 6. Proc Natl Acad Sci USA 1990; 87: 4068-72
7. Yee C, Biondi A, Wang XH et al. A possible autocrine role for interleukin-6 in two lymphoma cell lines. Blood 1989; 74: 798-804
8. Kawano M, Hirano T, Matsuda T et al. Autocrine generation and requirement of BSF/IL-6 for human multiple myelomas. Nature (Lond) 1988; 332: 82-5
9. Eustace D, Han X, Gooding R, Rowbottom A, Riches P, Heyderman E. Interleukin-6 (IL-6) functions as an autocrine growth factor in cervical carcinomas in vitro. Gynecol Oncol 1993; 59: 15-9
10. Teranishi T, Hirano T, Naomichi A, Onoue K. Human helper T cell factor(s) (ThF). II. Induction of IgG production in B lymphoblastoid cell lines and identification of T cell-replacing factor-(TRY) like factor(s). J Immunol 1982; 128: 193-8
11. Hirano T, Teranishi T, Lin B, Onoue K. Human helper T cell factor(s). IV. Demonstration of a human late-acting B cell differentiation factor acting on Staphylococcus aureus Cowan 1-stimulated B cells. J Immunol 1984; 133: 798-802
12. Bowcock AM, Kidd JR, Lathrop M et al. The human 'beta-2 interferon/hepatocyte stimulating factor/interleukin-6' gene. DNA polymorphism studies and localisation to chromosome 7p21. Genomics 1988; 3: 8-16
13. Yasukawa K, Hirano T, Wantanabe Y, Muratani K, Matsuda T, Kishimoto T. Structure and expression of human B cell stimulatory factor-2 (BSF-2/IL-6) gene. EMBO J 1987; 6: 2939-45
14. Maliner-Stratton MS, Klein RD, Udayakumar TS, Nagle Rae Bourke, Bowden GT. Interleukin-1beta-induced promatrilysin expression is mediated by NfkappaB-regulated synthesis of interleukin-6 in the prostate cancer cell line, LNCaP. Neoplasia 2001; 3: 509-20
15. Hirano T, Yasukawa K, Harada H et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 1986; 324: 73-6
16. Simpson RJ, Moritz RL, Van Roost E, Van Snick J. Characterisation of a recombinant murine interleukin-6: assignment of disulfide bonds. Biochem Biophys Res Commun 1988; 157: 364-72
17. Van Snick J. Interleukin-6: an overview. Annu Rev Immunol 1990; 8: 253-78
18. May LT, Grayeb J, Santhanam U et al. Synthesis and secretion of multiple forms of b2-interferon/B cell differentiation factor/hepatocyte-stimulating factor by human fibroblasts and monocytes. J Biol Chem 1988; 263: 7760-6
19. May LT, Santhanam U, Tatter SB et al. Phosphorylation of secreted forms of human b2-interferon/hepatocyte-stimulating factor/interleukin-6. Biochem Biophys Res Commun 1988; 152: 1144-50
20. Cayphas S, Van Damme J, Vink A, Simpson RJ, Billiau A, Van Snick J. Identification of an interleukin HP-1 like plasmacytoma growth factor produced by L cells in response to viral infection. J Immunol 1987; 139: 2965-9
21. Nordan R, Potter M. A macrophage-derived factor required by plasmacytomas for survival and proliferation in vitro. Science 1986; 223: 566-9
22. Shalaby MR, Waage A, Espevik T. Cytokine regulation of interleukin 6 production by human endothelial cells. Cell Immunol 1989; 121: 372-82
23. Van Damme J, Cayphas S, Opdenakker G, Billiau A, Van Snick J. Interleukin-1 and poly[rl) poly[rC) induce production of a hybridoma growth factor by human fibroblasts. Eur J Immunol 1987; 17: 1-7
24. Kohase M, May LT, Tamm I, Vilcek J, Sehgal PB. A cytokine network in human diploid fibroblasts: interactions of β-interferons, tumour necrosis factor, platelet-derived growth factor, and interleukin-1. Mol Cell Biol 1987; 7: 273-80
25. Zhang Y, Lin JX, Vilcek J. Synthesis if interleukin 6 (interferon β2/B cell stimulatory factor 2) in human fibroblasts is triggered by an increase in intracellular cyclic AMP. J Biol Chem 1988; 263: 6177-82
26. Sehgal PB, Walther Z, Tamm I. Rapid enhancement of b2-IFN/BSF-2 gene expression in human fibroblasts by diacylglycerols and the calcium ionophore A23187. Proc Natl Acad Sci USA 1987; 84: 3633-7
27. Lotz M, Jirik F, Kabouridis R et al. B cell stimulating factor 2/interleukin 6 is a costimulant for human thymocytes and T lymphocytes. J Exp Med 1988; 167: 1253-8
28. Takai Y, Wong G, Clark S, Burakoff S, Herrmann S. B cell stimulatory factor-2 is involved in the differentiation of cytotoxic T lymphocytes. J Immunol 1988; 140: 508-12
29. Ritchie DG, Fuller GM. Hepatocyte-stimulating factor: a monocyte-derived acute-phase regulatory protein. Ann N Y Acad Sci 1983; 408: 490-500
30. Koj A. Definition and classification of acute phase proteins in the acute phase response to injury and infection. In Gordon AH, Koj A eds, The acute phase response to injury and infection: The roles of interleukin-1 and other mediators. Chapt 10. Amsterdam: Elsevier, 1985: 139-232
31. Helle M, Brackenhoff J, De Groot E, Aarden L. Interleukin-6 is involved in interleukin-1-induced activities. Eur J Immunol 1988; 18: 957-9
32. Marinkovic S, Jahreis GP, Wong GG, Baumann H. IL-6 modulates the synthesis of a specific set of acute phase proteins in vivo. J Immunol 1989; 142: 808-12
33. Kishimoto T, Akira S, Narazaki M, Taga T. Interleukin-6 family of cytokines and gp130. Blood 1995; 86: 1243-54
34. Imada K, Leonard WJ. The Jak-STAT pathway. Mol Immunol 2000; 37: 1-11
35. Murakami M, Hibi M, Nakagawa T, Yasukawa K, Taga T, Kishimoto T. IL-6 induced homodimerization of gp130 and associated activation of a tyrosine kinase. Science 1993; 260: 1808
36. Wilks AF, Harper AG, Kurban RR, Ralph SJ, Zurcher G, Ziemiecki A. Two novel protein-tyrosine linases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase. Mol Cell Biol 1991; 11: 2057-65
37. Aringer M, Cheng A, Nelson JW et al. Janus kinases and their role in growth and disease. Life Sci 1999; 64: 2173-86
38. Takeda K, Kaisho T, Yoshida N, Takeda J, Kishimoto T, Akira S. Stat3 activation is responsible for IL-6-dependent T-cell proliferation through preventing apoptosis, generation and characterization of T cell specific Stat3-deficient mice. J Immunol 1998; 161: 4652-60
39. Shaefer TS, Sanders LK, Nathans D. Cooperative transcriptional activity of Jun and Stat3b, a short form of Stat3. Proc Natl Acad Sci USA 1995; 92: 9097-101
40. Zhang Z, Jones S, Hagood JS, Fuentes NL, Fuller GM. STAT3 acts as a co-activator of glucocorticoid receptor signalling. J Biol Chem 1997; 272: 30607-10
41. Akira S. IL-6-regulated transcription factors. Int J Biochem Cell Biol 1997; 29: 1401-18
42. Garrington TP, Johnson GL. Organization and regulation of mitogen-activated protein kinase signalling pathways. Curr Opin Cell Biol 1999; 11: 211-8
43. Genot E, Cantrell DA. Ras regulation and function in lymphocytes. Curr Opin Immunol 2000; 12: 289-94
44. Lopez-Ilasaca M. Signalling from G-protein-coupled receptors to mitogen-activated protein (MAP)-kinase cascades. Biochem Pharmacol 1998; 56: 269-77
45. Hobisch A, Eder IE, Putz T et al. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res 1998; 58: 4640-5
46. Ueda T, Bruchovsky N, Sadar MD. Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J Biol Chem 2002; 277: 7076-85
47. Chen T, Wang LH, Farrar WL. Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells. Cancer Res 2000; 60: 2132-5
48. Lin D-L, Whitney MC, Yao Z, Keller ET. Interleukin-6 induces androgen responsiveness in prostate cancer cells through up-regulation of androgen receptor expression. Clin Cancer Res 2001; 7: 1773-81
49. Qiu Y, Ravi L, Kung HJ. Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells. Nature 1998; 393: 83-5
50. Qiu Y, Robinson D, Pretlow TG, Kung HJ. Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3′-kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells. Proc Natl Acad Sci USA 1998; 95: 3644-9
51. Siegsmund MJ, Yamazaki H, Pastan I. Interleukin 6 receptor mRNA in prostate carcinomas and benign prostate hyperplasia. J Urol 1994; 151: 1396-9
52. Hobisch A, Rogatsch H, Hittmair A et al. Immunohistochemical localisation of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue. J Pathol 2000; 191: 239-44
53. Giri D, Ozen M, Ittmann M. Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol 2001; 159: 2159-65
54. Twillie DA, Eisenberger MA, Carducci MA, Hseih W, Kim WY, Simons JW. Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology 1995; 45: 542-9
55. Hoosein N, Abdul M, McCabe R et al. Clinical significance of elevation in neuroendocrine factors and interleukin-6 in metastatic prostate cancer. Urol Oncol 1995; 1: 246-51
56. Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT, Thompson TC. Elevated levels of circulating Interleukin-6 and transforming growth factor-β1 in patients with metastatic prostate carcinoma. J Urol 1999; 161: 182-7
57. Wise GJ, Marella VK, Talluri G, Shirazian D. Cytokine variations in patients with hormone treated prostate cancer. J Urol 2000; 164: 722-5
58. Drachenberg DE, Elgamal AA, Rowbotham R, Peterson M, Murphy GP. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate 1999; 41: 127-33
59. Nakashima J, Tachibana M, Horiguchi Y et al. Serum interleukin-6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 2000; 6: 2702-6
60. Shariat SF, Andrews B, Kattan MW, Kim J, Wheeler TM, Slawin KM. Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology 2001; 58: 1008-15
61. Siegall CB, Schwab G, Nordan RP, Fitzgerald DJ, Pastan I. Expression of the interleukin 6 receptor and interleukin 6 in prostate carcinoma cells. Cancer Res 1990; 50: 7786-8
62. Okamoto M, Lee C, Oyasu R. Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res 1997; 57: 141-6
63. Chung TDK, Yu JJ, Spiotto MT, Bartkowski M, Simons JW. Characterization of the role of IL-6 in the progression of prostate cancer. Prostate 1999; 38: 199-207
64. Lou W, Ni Z, Dyer K, Tweardy DJ, Gao AC. Interleukin-6 induces prostate cancer cell growth accompanied by activation of Stat3 signalling pathway. Prostate 2000; 42: 239-42
65. Borsellino N, Belldegrun A, Bonavida B. Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res 1995; 55: 4633-9
66. Ni Z, Lou W, Leman ES, Gao AC. Inhibition of constitutively activated Stat3 signalling pathway suppresses growth of prostate cancer cells. Cancer Res 2000; 60: 1225-8
67. Mori S, Murakami-Mori K, Bonavida B. Interleukin-6 induces G1 arrest through induction of p27Kip1, a cyclin dependent kinase inhibitor, and neuron-like morphology in LNCaP prostate tumour cells. Biochem Biophys Res Commun 1999; 257: 609-14
68. di Sant'Agnese PA. Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic and therapeutic implications. Cancer 1992; 70: 254-68
69. Hobisch A, Ramoner R, Fuchs D et al. Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype. Clin Cancer Res 2001; 7: 2941-8
70. Stratton MS, Sirvent H, Udayakumar TS, Nagle Rae Bourke, Bowden GT. Expression of the matrix metalloproteinase promatrilysin in coculture of prostate carcinoma cell lines. Prostate 2001; 48: 206-9
71. Garcia-Moreno C, Mendez-Davila C, de la Piedra C, Casto-Errecaborde NA, Traba ML. Human prostatic carcinoma cells produce an increase in the synthesis of interleukin-6 by human osteoblasts. Prostate 2002; 50: 241-6
72. Smith PC, Keller ET. Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice. Prostate 2001; 48: 47-53
73. Mishimura K, Nonomura N, Yasunaga Y et al. Low doses of oral dexamethasone for hormone-refractory prostate carcinoma. Cancer 2000; 89: 2570-6
74. Nishimura K, Nonomura N, Satoh E et al. Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer. J Natl Cancer Inst 2001; 93: 1739-46